The Business Group of the Biotechnological and Pharmaceutical Industries of Cuba (Biocubafarma) today highlighted the new clinical evidence of safety and therapeutic effect of the national HeberSaVax vaccine, which constituted an achievement of science and innovation in the country in 2022.
Through Twitter, Biocubafarma published the recognition it granted to the executing entities of the immunogen also known as CIGB 247, used in the treatment of hepatocellular carcinoma and ovarian cancer in advanced stages.
The new clinical evidence of safety and therapeutic effect of the #vaccine #HeberSaVax for the treatment of #cancers of liver and ovary, was another achievement of science and innovation in 2022 that received recognition from @BioCubaFarma. Congratulations!!! pic.twitter.com/voBayhus9R
— CIGBCuba (@CIGBCuba) January 16, 2023
Among the institutions participating in the development of HeberSaVax are the Center for Genetic Engineering and Biotechnology (CIGB), the Center for Surgical Medical Research (CIMEQ), the Ministry of Public Health, the Institute of Cybernetics, Mathematics and Physics (ICIMAF) and the Central University Marta Abreu de Las Villas.
Recently, at a meeting of experts and scientists for health issues with President Miguel Díaz-Canel, it emerged that HeberSaVax is a safe and tolerable product, with minimal adverse reactions, which was concluded after 10 years of continuous immunizations in clinical trials.
Dr. Francisco Hernández, clinical manager of the development of CIGB 247, affirmed that it is a Cuban therapeutic alternative, safe and less expensive compared to others that exist in the world, available to patients suffering from a complex health problem.
During the meeting, it was recognized that the Cuban drug has demonstrated an immune response in humans in the treatment of hepatocarcinoma, the fifth most frequent cancer worldwide, which causes more than half a million deaths annually.
When one sees that a median survival of 11 months is achieved against the leading product in the world, Sorafenib (which does not exceed six months), there is no doubt that it is very powerful clinical evidence, he stated on that occasion. the specialist in Gastroenterology-Hepatology and endoscopist, Enrique Arús Soler.
